| A phase 2 study of bortezomib in relapsed, refractory myeloma PG Richardson, B Barlogie, J Berenson, S Singhal, S Jagannath, D Irwin, ... New England Journal of Medicine 348 (26), 2609-2617, 2003 | 3440 | 2003 |
| International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma S Kumar, B Paiva, KC Anderson, B Durie, O Landgren, P Moreau, ... The lancet oncology 17 (8), e328-e346, 2016 | 2476 | 2016 |
| Revised international staging system for multiple myeloma: a report from International Myeloma Working Group A Palumbo, H Avet-Loiseau, S Oliva, HM Lokhorst, H Goldschmidt, ... Journal of clinical oncology 33 (26), 2863, 2015 | 2143 | 2015 |
| Daratumumab, lenalidomide, and dexamethasone for multiple myeloma MA Dimopoulos, A Oriol, H Nahi, J San-Miguel, NJ Bahlis, SZ Usmani, ... New England Journal of Medicine 375 (14), 1319-1331, 2016 | 1576 | 2016 |
| Elotuzumab therapy for relapsed or refractory multiple myeloma S Lonial, M Dimopoulos, A Palumbo, D White, S Grosicki, I Spicka, ... New England Journal of Medicine 373 (7), 621-631, 2015 | 1501 | 2015 |
| Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1 SV Rajkumar, JL Harousseau, B Durie, KC Anderson, M Dimopoulos, ... Blood, The Journal of the American Society of Hematology 117 (18), 4691-4695, 2011 | 1124 | 2011 |
| Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma A Palumbo, SV Rajkumar, MA Dimopoulos, PG Richardson, J San Miguel, ... Leukemia 22 (2), 414-423, 2008 | 1022 | 2008 |
| Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ... Leukemia 26 (1), 149-157, 2012 | 1007 | 2012 |
| Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label … MA Dimopoulos, P Moreau, A Palumbo, D Joshua, L Pour, R Hájek, ... The Lancet Oncology 17 (1), 27-38, 2016 | 988 | 2016 |
| Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial S Lonial, BM Weiss, SZ Usmani, S Singhal, A Chari, NJ Bahlis, A Belch, ... The Lancet 387 (10027), 1551-1560, 2016 | 971 | 2016 |
| Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies RZ Orlowski, TE Stinchcombe, BS Mitchell, TC Shea, AS Baldwin, S Stahl, ... Journal of Clinical Oncology 20 (22), 4420-4427, 2002 | 944 | 2002 |
| Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group P Sonneveld, H Avet-Loiseau, S Lonial, S Usmani, D Siegel, ... Blood, The Journal of the American Society of Hematology 127 (24), 2955-2962, 2016 | 933 | 2016 |
| Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem … BGM Durie, A Hoering, MH Abidi, SV Rajkumar, J Epstein, SP Kahanic, ... The Lancet 389 (10068), 519-527, 2017 | 919 | 2017 |
| Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma DJ Kuhn, Q Chen, PM Voorhees, JS Strader, KD Shenk, CM Sun, ... Blood, The Journal of the American Society of Hematology 110 (9), 3281-3290, 2007 | 885 | 2007 |
| Daratumumab plus lenalidomide and dexamethasone for untreated myeloma T Facon, S Kumar, T Plesner, RZ Orlowski, P Moreau, N Bahlis, S Basu, ... New England Journal of Medicine 380 (22), 2104-2115, 2019 | 870 | 2019 |
| Proteasome inhibitors in cancer therapy EE Manasanch, RZ Orlowski Nature reviews Clinical oncology 14 (7), 417-433, 2017 | 854 | 2017 |
| A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma DS Siegel, T Martin, M Wang, R Vij, AJ Jakubowiak, S Lonial, S Trudel, ... Blood, The Journal of the American Society of Hematology 120 (14), 2817-2825, 2012 | 808 | 2012 |
| Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib PG Richardson, H Briemberg, S Jagannath, PY Wen, B Barlogie, ... J Clin Oncol 24 (19), 3113-3120, 2006 | 783 | 2006 |
| NF-κB as a therapeutic target in cancer RZ Orlowski, AS Baldwin Trends in molecular medicine 8 (8), 385-389, 2002 | 779 | 2002 |
| Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy … RZ Orlowski, A Nagler, P Sonneveld, J Bladé, R Hajek, A Spencer, ... Journal of Clinical Oncology 25 (25), 3892-3901, 2007 | 776 | 2007 |
